Lifesci Capital Has Pessimistic View of Immunome Q3 Earnings

Immunome, Inc. (NASDAQ:IMNM) – Research analysts at Lifesci Capital cut their Q3 2026 EPS estimates for shares of Immunome in a note issued to investors on Monday, December 15th. Lifesci Capital analyst C. Zhu now anticipates that the company will earn ($0.59) per share for the quarter, down from their previous forecast of ($0.55). The consensus estimate for Immunome’s current full-year earnings is ($2.21) per share. Lifesci Capital also issued estimates for Immunome’s Q4 2026 earnings at ($0.57) EPS and FY2026 earnings at ($2.44) EPS.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%.

Other equities analysts have also recently issued reports about the company. Craig Hallum began coverage on Immunome in a research note on Friday, September 5th. They set a “buy” rating and a $26.00 target price on the stock. Stephens boosted their price objective on shares of Immunome from $25.00 to $33.00 and gave the company an “overweight” rating in a research report on Monday, November 17th. The Goldman Sachs Group initiated coverage on shares of Immunome in a report on Monday, September 22nd. They issued a “buy” rating and a $26.00 price objective for the company. Leerink Partners set a $40.00 target price on shares of Immunome in a research report on Monday. Finally, Guggenheim boosted their price target on shares of Immunome from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Immunome currently has a consensus rating of “Moderate Buy” and a consensus target price of $30.09.

Immunome Price Performance

IMNM opened at $19.78 on Thursday. Immunome has a one year low of $5.15 and a one year high of $25.30. The business has a 50 day simple moving average of $17.42 and a two-hundred day simple moving average of $12.55. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of -6.71 and a beta of 2.17.

Institutional Trading of Immunome

Hedge funds and other institutional investors have recently modified their holdings of the business. Assetmark Inc. bought a new position in shares of Immunome in the 3rd quarter worth about $39,000. BNP Paribas Financial Markets grew its holdings in Immunome by 81.8% in the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after purchasing an additional 2,909 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Immunome by 121.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock valued at $65,000 after purchasing an additional 3,802 shares in the last quarter. BIT Capital GmbH bought a new position in shares of Immunome during the third quarter valued at approximately $69,000. Finally, Russell Investments Group Ltd. purchased a new position in shares of Immunome during the third quarter valued at approximately $76,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.